Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02573233 · ClinicalTrials.gov registry record · Phase 2
Evaluation of Dupilumab's Effects on Airway Inflammation in Patients With Asthma
A Phase 2 study of Asthma, sponsored by Sanofi.
- Completed
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
- 16
- Study locations
NCT02573233: Completed Phase 2 study of Asthma, sponsored by Sanofi.
NCT02573233 is a Phase 2 study of Asthma that has completed, run by Sanofi. The registered enrollment target is 42 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (97% lower). The trial reports 16 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02573233, a Phase 2 study of Asthma, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
- 16
- Study locations
Study Summary
Primary Objective: To evaluate the effect of dupilumab, compared to placebo, on airway inflammation in participants with persistent asthma. Secondary Objective: To assess the safety, tolerability, and immunogenicity of dupilumab compared to placebo.
Primary Outcome
Inflammatory cells i.e. eosinophils were counted in the bronchial submucosa of biopsy thin sections using quantitative immunohistochemistry and reported as the number of cells per square millimeter.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Dupilumab SAR231893/REGN668
- DRUG fluticasone propionate and salmeterol
- DRUG budesonide and formoterol
- DRUG mometasone furoate and formoterol
Study Locations (16)
Other
- Investigational Site Number 124012 - Montreal
- Investigational Site Number 124018 - Sainte-Foy
- Investigational Site Number 208002 - Hvidovre
- Investigational Site Number 208001 - København NV
- Investigational Site Number 276013 - Frankfurt am Main
- Investigational Site Number 276011 - Großhansdorf
- Investigational Site Number 276012 - Hanover
- Investigational Site Number 752001 - Lund
- Investigational Site Number 826010 - London
- Investigational Site Number 826009 - Oxford
Arizona
- Investigational Site Number 840402 - Tucson
Colorado
- Investigational Site Number 840403 - Denver
Massachusetts
- Investigational Site Number 840401 - Boston
Missouri
- Investigational Site Number 840002 - St Louis
North Carolina
- Investigational Site Number 840404 - Winston-Salem
Pennsylvania
- Investigational Site Number 840028 - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2016-01-27 |
| Est. Completion | 2018-01-03 |
| Phase | Phase 2 |
What the finished NCT02573233 record still lists
NCT02573233 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 5 interventions - of which Placebo is the first listed.
NCT02573233 lists 16 locations in 7 states (Other, Arizona, Colorado).
Frequently Asked Questions
What is clinical trial NCT02573233 about?
NCT02573233 is a clinical study titled "Evaluation of Dupilumab's Effects on Airway Inflammation in Patients With Asthma". Primary Objective: To evaluate the effect of dupilumab, compared to placebo, on airway inflammation in participants with persistent asthma. Secondary Objective: To assess the safety, tolerability, and immunogenicity of dupilumab compared to placebo.
What is the current status of trial NCT02573233?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2016-01-27. Estimated completion is 2018-01-03.
What conditions does trial NCT02573233 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT02573233?
The interventions under investigation include: Placebo (DRUG), Dupilumab SAR231893/REGN668 (DRUG), fluticasone propionate and salmeterol (DRUG), budesonide and formoterol (DRUG), mometasone furoate and formoterol (DRUG).
Who is sponsoring clinical trial NCT02573233?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02573233 being conducted?
This trial has 16 study locations across Arizona, Colorado, Massachusetts, Missouri, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02573233's enrollment target sits among peer trials
42 280th of 374 higher than 95 of 374 other Asthma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Asthma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Escitalopram in Asthma Patients With Frequent Exacerbation
RECRUITING · Phase 2
-
Metformin IN Asthma for Overweight and Obese Individuals (MINA)
RECRUITING · Phase 2
-
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
RECRUITING · Phase 2
-
ENV-294 for Moderate-to-Severe Asthma: A 12-Week Study in Adults
RECRUITING · Phase 2
-
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
RECRUITING · Phase 2
-
Supplementing L-citrulline to Overweight Late Asthma oNset Phenotypes
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI